Application of EPC subgroup in ischemic diseases

By identifying and utilizing biomarkers of advanced EPC, the preparation of pharmaceutical compositions for treatment is solved in the prior art treatment problems of lower limb ischemic diseases, improving the therapeutic effect, and reducing the amputation rate and mortality rate.

CN119074772AActive Publication Date: 2024-12-06ALLIFE REGENERATIVE MEDICINE TECH BEIJING CO LTD

Patent Information

Application Number
CN202411256696.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

The prior art is difficult to improve limb blood perfusion and related clinical symptoms in patients with lower limb ischemic diseases through non-surgical methods, resulting in a higher amputation rate and mortality rate.

Method used

Discover and use advanced EPC as an effective ingredient in the treatment of ischemic diseases, distinguish and enrich late EPC by identifying biomarkers CD144, vWF and CD133, prepare pharmaceutical compositions for treatment, and provide identification, sorting, isolation and enrichment methods.

Benefits of technology

It improves the therapeutic effect of ischemic diseases, especially lower limb ischemia, provides new non-surgical treatment methods, and reduces the amputation rate and mortality rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074772A_ABST
    Figure CN119074772A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and discloses application of an EPC subgroup in ischemic diseases. According to the invention, the index for distinguishing the EPC subgroups, namely CD144, vWF, CD133 or phagocytic ability, is found for the first time, and based on the index, the invention discloses a method for identifying, sorting, separating or enriching the EPC subgroups.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to the application of EPC subpopulations in ischemic diseases. Background Art

[0002] As the aging population continues to accelerate, the incidence of peripheral arterial disease (PAD) is increasing year by year. About 10% of PAD patients further develop critical limb ischemia (CLI), with clinical manifestations of rest pain (lasting more than 2 weeks), ulcers, or gangrene. The quality of life index of CLI patients is similar to that of advanced cancer patients, and their mortality rate exceeds 50% within 5 years after the initial diagnosis (Kitrou P, et al. Gene-based therapies in patients with critical limb ischemia. Expert Opin Biol Ther 2017, 17 (4): 449-456.). Traditional surgical or endovascular treatment is currently the clinical first choice for CLI patients, but about 30% of patients are still not suitable for surgery or endovascular treatment due to severe complications. Therefore, improving limb blood perfusion and related clinical symptoms of CLI patients through non-surgical treatment and reducing amputation rate and mortality are clinical problems that need to be solved urgently. Summary of the invention

[0003] In order to solve the problems existing in the prior art, the inventors of the present invention have conducted extensive and in-depth research and discovered for the first time that late EPC rather than early EPC has the effect of treating ischemic diseases, especially lower limb ischemia, providing a new and effective treatment for ischemic diseases, especially lower limb ischemia.

[0004] The present invention also discovered biomarkers for distinguishing early EPCs from late EPCs, and the use of relevant biomarkers can be used for identification, sorting, separation and enrichment of different EPC subpopulations. It can also be used to determine the purity of differentiated products, quantify EPC subpopulations in samples, and screen candidate drugs for regulating EPC subpopulations.

[0005] Based on this, the present invention provides the following technical solutions:

[0006] The first aspect of the present invention provides the use of late EPC in the preparation of a medicament for treating ischemic diseases.

[0007] A second aspect of the present invention provides a pharmaceutical composition for treating ischemic diseases, wherein the pharmaceutical composition comprises late EPC.

[0008] A third aspect of the present invention provides a method for identifying an EPC subpopulation, the method comprising determining the expression of at least one biomarker in a cell, the biomarker comprising CD144, vWF or CD133; and

[0009] When it is determined that the cell has at least one of the following expression profiles, the EPC is a late EPC: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - When it is determined that the cell has at least one of the following expression profiles, the EPC cell is an early EPC: CD133 高 / + 、CD144 低 / - 、vWF 低 / - .

[0010] A fourth aspect of the present invention provides a method for identifying EPC subpopulations, the method comprising detecting the phagocytic ability of cells.

[0011] A fifth aspect of the present invention provides a method for sorting, isolating or enriching late EPCs from a cell population, selecting cells having at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + and / or CD 133 低 / - .

[0012] A sixth aspect of the present invention provides a method for sorting, isolating or enriching early EPCs from a cell population, wherein cells CD133 having at least one of the following expression profiles are selected: 高 / + 、CD144 低 / - and / or vWF 低 / - .

[0013] The seventh aspect of the present invention provides a product comprising a binding agent for the biomarker, wherein the biomarker includes CD144, vWF and / or CD133.

[0014] An eighth aspect of the present invention provides a method for determining the purity of a differentiation product, the method comprising:

[0015] The expression level of at least one biomarker of cells in the sample of the differentiation product is detected, wherein the biomarker is selected from CD144, vWF and / or CD133; and the purity of the differentiation product is determined according to the expression level of the biomarker.

[0016] A ninth aspect of the present invention provides a method for quantifying EPC subpopulations in a sample, the method comprising:

[0017] The expression level of at least one biomarker of cells in the target sample is detected, wherein the biomarker is selected from CD144, vWF and / or CD133; and the content of the EPC subpopulation is determined according to the expression level of the biomarker.

[0018] The tenth aspect of the present invention provides a method for screening candidate drugs that regulate EPC subpopulations, the method comprising adding the drug to be screened to a cell population, detecting the expression level of a biomarker of the cell, wherein the biomarker is selected from CD144, vWF and / or CD133; when the drug to be screened changes the expression level of the cell marker, the drug to be screened is a candidate drug for regulating EPC subpopulations.

[0019] The eleventh aspect of the present invention provides a method for treating ischemic diseases, comprising administering to a subject an effective amount of advanced EPC or the pharmaceutical composition according to the tenth aspect of the present invention.

[0020] Advantages and beneficial effects of the present invention:

[0021] The present invention discovers for the first time that late EPCs rather than early EPCs can be used to treat ischemic diseases, especially lower limb ischemia. Based on this, the therapeutic effect of endothelial progenitor cells in treating ischemic diseases can be improved by increasing the content of late EPCs, which are the active ingredients of ischemic diseases.

[0022] The present invention is the first to discover biomarkers that distinguish early and late EPCs. Based on the biomarkers, different EPC subpopulations can be identified, sorted, isolated and enriched.

[0023] The present invention also provides a method for determining the purity of a differentiation product, a method for quantifying EPC subpopulations in a sample, and a method for screening candidate drugs for regulating EPC subpopulations.

[0024] The present invention first discovered that phagocytic ability can be used to distinguish early EPCs from late EPCs. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the result of early EPC cell surface marker gene detection;

[0026] Figure 2 This is the result of late EPC cell surface marker gene detection;

[0027] Figure 3 This is a graph showing the results of early EPC surface marker gene detection by flow cytometry;

[0028] Figure 4 This is the result of flow cytometry detection of late EPC surface marker gene;

[0029] Figure 5 This is a graph showing the results of the phagocytic ability test;

[0030] Figure 6 It is the laser speckle blood flow detection image;

[0031] Figure 7 It is a statistical chart of lower limb ischemia rate in mice. DETAILED DESCRIPTION

[0032] It should be understood that the terms used in the present invention are only used for the purpose of describing specific embodiments and are not intended to be limiting. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although other methods and materials similar to or equivalent to the methods and materials described in the present invention are available in the present invention, the present invention describes preferred materials and methods.

[0033] As used herein, "subject," "individual," or "patient" are used interchangeably herein and refer to any member of the phylum Chordata, including but not limited to humans and other primates, including non-human primates, such as rhesus macaques, chimpanzees, and other monkeys and apes; farm animals, such as cattle, sheep, pigs, goats, and horses; domestic mammals, such as dogs and cats; laboratory animals, including rabbits, mice, rats, and guinea pigs; birds, including poultry, wild birds, and game birds, such as chickens, turkeys, and other gallinaceous birds, ducks, and geese; and the like. The term does not denote a particular age or sex. Thus, the term includes adult, young, and newborn individuals, as well as males and females. In some embodiments, cells (e.g., stem cells, including pluripotent stem cells, progenitor cells, or specific tissue cells) are derived from a subject.

[0034] As used in the present invention, "induced pluripotent stem cells (iPSC)" refers to a class of pluripotent stem cells artificially derived from non-pluripotent cells (usually somatic cells). In some embodiments, somatic cells are human cells. Examples of somatic cells include, but are not limited to, dermal fibroblasts, mesenchymal cells derived from bone marrow, cardiomyocytes, keratinocytes, hepatocytes, gastric cells, neural stem cells, lung cells, kidney cells, spleen cells, and pancreatic cells. Other examples of somatic cells include cells of the immune system, including but not limited to B cells, dendritic cells, granulocytes, natural lymphocytes, megakaryocytes, monocytes / macrophages, suppressor cells derived from bone marrow, natural killer (NK) cells, T cells, thymocytes, and hematopoietic stem cells.

[0035] As used herein, "binding" refers to non-covalent interactions between macromolecules (e.g., between a protein and a polynucleotide, between a polynucleotide and a polynucleotide, or between a protein and a protein, etc.). Such non-covalent interactions are also referred to as "association" or "interaction" (e.g., if a first macromolecule interacts with a second macromolecule, the first macromolecule binds to the second macromolecule in a non-covalent manner). Certain portions of the binding interactions may be sequence-specific.

[0036] As used herein, the term "regulation" refers to a change in the quantity, degree or number of properties, activities, functions or physical molecules. Regulation can be determined by determining any characteristic that is directly or indirectly affected by the expression of the target gene. These characteristics include, for example, changes in RNA or protein levels, protein activity, product levels, expression of a gene or activity levels of a reporter gene.

[0037] After extensive and in-depth research, the present invention has discovered indicators that can be used to distinguish early and late EPCs by studying different EPC subgroups, and further proved that late EPCs rather than early EPCs have the effect of treating ischemic diseases, especially lower limb ischemia.

[0038] In one aspect, the present invention provides the use of late EPC in the preparation of a medicament for treating ischemic diseases.

[0039] In some embodiments, the late EPCs have at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - .

[0040] In some embodiments, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + and CD 133 低 / - combination.

[0041] In some embodiments, the late EPCs also have at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + .

[0042] In some embodiments, the late EPCs have the following expression profile: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + .

[0043] In some embodiments, the EPCs are derived from iPSCs.

[0044] In some embodiments, the ischemic disease is selected from lower limb ischemia.

[0045] Another aspect of the present invention provides a pharmaceutical composition for treating ischemic diseases, wherein the pharmaceutical composition comprises late EPC.

[0046] In some embodiments, the late EPCs have at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - .

[0047] In some embodiments, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + and CD 133 低 / - combination.

[0048] In some embodiments, the late EPCs also have at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + .

[0049] In some embodiments, the late EPCs have the following expression profile: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + .

[0050] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0051] "Pharmaceutically acceptable" refers to a composition that is physiologically acceptable and does not usually cause gastrointestinal disorders, dizziness, or other allergic reactions or similar reactions when administered to humans. Pharmaceutically acceptable carriers include non-oral administration carriers such as water, appropriate oils, physiological saline, aqueous glucose, and ethylene glycol, and may also contain stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methylparaben or propylparaben, and trichlorobutanol.

[0052] Furthermore, the above-mentioned pharmaceutical composition can also be administered via any device that can move the pharmaceutical composition to the target cells.

[0053] The pharmaceutical composition of the present invention can be administered by any common route that can reach the target tissue, and can be administered parenterally, such as intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, and intradermal administration, but is not limited thereto.

[0054] In some embodiments, the pharmaceutical composition of the present invention can have any dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, infusions, internal solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, oils, freeze-dried agents and suppositories.

[0055] In some embodiments, the pharmaceutical composition is in the form of an infusion.

[0056] In some embodiments, the infusion of the present invention comprises an infusion solution, such as normal saline, sodium lactate Ringer's solution, compound electrolyte injection, 5% glucose injection, 20% HSA injection, succinylated gelatin injection, succinylated gelatin MIX injection, MZJ injection 1, MZJ injection 2, MZJ injection 3, human serum albumin injection, Bolili A, potassium chloride injection, magnesium sulfate injection, sodium bicarbonate injection, glucose sodium chloride injection, compound sodium chloride injection (Ringer's solution), dextran 20 glucose injection (small molecule), amino acid injection, hydroxyethyl Hydroxyethyl starch 40 sodium chloride injection, hydroxyethyl starch 40 sodium chloride injection, hydroxyethyl starch 40 sodium chloride injection, low molecular weight heparin calcium for injection, heparin sodium injection, coenzyme A for injection, cytidine triphosphate disodium, lysine hydrochloride for injection, vitamin C injection, citicoline sodium chloride, fat-soluble vitamin II for injection, reduced glutathione for injection, brain protein hydrolysate for injection, sodium deoxyribonucleotide injection, multiple trace elements injection II, mannitol injection, arginine hydrochloride injection, potassium chloride injection, cytidine triphosphate disodium for injection, ornithine aspartate injection, etc.

[0057] The infusion of the present invention may also contain one or more additives, for example, selected from solubilizers, wetting agents, emulsifiers, buffers, suspending agents, chelating agents, antioxidants, antibacterial agents, local anesthetics, isotonicity regulators, fillers, protective agents and any combination thereof.

[0058] In some embodiments, the ischemic disease is selected from lower limb ischemia.

[0059] In another aspect, the present invention provides a method for identifying an EPC subpopulation, the method comprising determining the expression of at least one biomarker in a cell, the biomarker comprising CD144, vWF or CD133; and

[0060] When it is determined that the cell has at least one of the following expression profiles, the EPC is a late EPC: CD144高 / + 、vWF 高 / + 、CD 133 低 / - When it is determined that the cell has at least one of the following expression profiles, the EPC cell is an early EPC: CD133 高 / + 、CD144 低 / - 、vWF 低 / - .

[0061] The biomarkers of the present invention may be detected alone, in combination, sequentially, simultaneously, synchronously, and / or in conjunction with other biomarkers, which may be specific for endothelial progenitor cells.

[0062] In some embodiments, the expression of one or more of the biomarkers listed above is determined to determine the presence of a subpopulation of EPCs in, for example, a composition, solution, cell aggregate, cell suspension, or tissue.

[0063] In some embodiments, the method further comprises the step of identifying the cell as an EPC.

[0064] In some embodiments, determining the expression of at least one biomarker in a cell comprises contacting the cell with a binding agent for the biomarker.

[0065] In the present invention, a binding agent refers to any compound, molecule and / or system that functions to detect the presence / absence and / or expression or level of a biomarker in the present invention. Such binding agents are capable of directly or indirectly detecting and / or binding to biomarkers. In the present invention, additional parts may be required to enhance the detection of biomarkers, for example, by / through amplifying optical diffraction. Examples of binding agents and additional parts include, but are not limited to, proteins (e.g., antigen binding proteins such as antibodies or fragments thereof, enzymes such as horseradish peroxidase and alkaline phosphatase, etc.), polynucleotides (e.g., aptamers) and small molecules (e.g., metal nanoparticles).

[0066] In some embodiments, biomarker expression can be assessed by any of a variety of well-known methods for detecting transcriptional molecules (e.g., mRNA) or protein expression. Non-limiting examples of these methods include immunological methods for detection, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.

[0067] Various amplification and detection methods can be used to assist in the detection of the expression of biomarkers. For example, reverse transcription of mRNA into cDNA (e.g., polymerase chain reaction, RT-PCR) prior to further analysis is within the scope of the present invention. Other known amplification methods that can be utilized in the present invention include, but are not limited to, "NASBA" or "3SR" techniques; Q-beta amplification; strand displacement amplification; targeted mediated amplification; ligase chain reaction (LCR); self-sustaining sequence replication (SSR); and transcription amplification.

[0068] Methods for detecting, characterizing and / or quantifying nucleic acid sequences; and methods for detecting, characterizing and / or quantifying mRNA expression are known to those skilled in the art and include, but are not limited to, for example, PCR procedures, RT-PCR, quantitative PCR or RT-PCR, Northern blot analysis, differential gene expression, RNA protection assays, microarray analysis, hybridization assays, serial analysis of gene expression (SAGE), hybridization based on digital barcode quantification, multiplex RT-PCR, digital droplet PCR (ddPCR), qRT-PCR, qPCR, UV spectroscopy, DNA sequencing, RNA sequencing, next generation sequencing, including RNAseq, lysate-based hybridization analysis using branched DNA signal amplification, such as QuantiGene 2.0 Single Plex, and branched DNA analysis methods.

[0069] Non-limiting examples of nucleic acid sequencing techniques, such as for DNA sequencing and RNA sequencing, include Maxam-Gilbert sequencing, Sanger sequencing (i.e., chain termination), synthetic sequencing (SBS), ligation sequencing, pyrophosphate sequencing, single molecule real-time sequencing, MiSeq sequencing, massively parallel signature sequencing (MPSS), polymerase clone sequencing, 454 sequencing, nanopore sequencing. The present invention also includes, but is not limited to, next generation sequencing technology.

[0070] Non-limiting examples of next generation sequencing technologies include, for example, Ion Torrent, Illumina, SOLiD, 454; massively parallel feature sequencing solid phase, reversible dye termination sequencing; and DNA nanoball sequencing. Digital barcode quantitative analysis can include BeadArray (Illumina), xMAP system (Luminex), nCounter (Nanostring), high throughput genomics (HTG) molecules, BioMark (Fluidigm), or Wafergen microarrays. Detection methods can include DASL (Illumina), RNA-Seq (Illumina), TruSeq (Illumina), SureSelect (Agilent), Bioanalyzer (Agilent), and TaqMan (ThermoFisher).

[0071] Another aspect of the present invention provides a method for identifying EPC subpopulations, the method comprising detecting the phagocytic ability of cells.

[0072] In some embodiments, the late EPC subpopulation has a greater phagocytic capacity than the early EPC subpopulation.

[0073] In some embodiments, the method detects the phagocytic ability of cells by detecting the uptake ability of acetylated LDL.

[0074] Another aspect of the present invention provides a method for sorting, isolating or enriching late EPCs from a cell population, selecting cells having at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + and / or CD 133 低 / - .

[0075] In some embodiments, the method comprises cells selected from the group consisting of: CD144 高 / + 、vWF 高 / + and CD133 低 / - .

[0076] In some embodiments, the method further comprises selecting cells having at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + .

[0077] In some embodiments, the method comprises selecting cells having the following expression profile: CD144 高 / + 、vWF 高 / + and / or CD 133 低 / - 、CD31 高 / +、CD34 高 / + and KDR 高 / + .

[0078] In some embodiments, the method further comprises culturing the late EPCs.

[0079] Another aspect of the present invention provides a method for sorting, isolating or enriching early EPCs from a cell population, wherein cells CD133 having at least one of the following expression profiles are selected: 高 / + 、CD144 低 / - and / or vWF 低 / - .

[0080] In some embodiments, the method comprises selecting cells expressing: CD133 高 / + 、CD144 低 / - and vWF 低 / - .

[0081] In some embodiments, the method further comprises selecting cells having at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and KDR 高 / + .

[0082] In some embodiments, the method comprises selecting cells having the following expression profile: CD133 高 / + 、CD144 低 / - and / or vWF 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + .

[0083] In some embodiments, the sorting or separation technique comprises fluorescence activated cell sorting, magnetic assisted cell sorting, substrate assisted cell sorting, laser mediated cutting, fluorimetry, flow cytometry, or microscopy.

[0084] In some embodiments, cells can be isolated by binding to an immobilized support and then harvested by removing the cells from the support.

[0085] Harvesting of cells can be achieved by collecting the separated cells into a suitable container or collection dish, test tube, or the like.

[0086] Another aspect of the present invention provides a product comprising a binding agent for the biomarker, wherein the biomarker comprises CD144, vWF and / or CD133.

[0087] In some embodiments, the biomarkers include a combination of CD144, vWF, and CD133.

[0088] In some embodiments, the biomarkers further include CD31, CD34 and / or KDR.

[0089] In some embodiments, the biomarkers include a combination of CD144, vWF, CD133, CD31, CD34, and KDR.

[0090] In some embodiments, the binding agent is selected from a nucleic acid, a ligand, an enzyme, a substrate, and / or an antibody.

[0091] In the present invention, "antibody" is used in the broadest sense and specifically covers, for example, monoclonal antibodies, polyclonal antibodies, antibodies with multiple epitope specificities, single-chain antibodies, multispecific antibodies and antibody fragments. Such antibodies can be chimeric, humanized, human and synthetic.

[0092] In some embodiments, the binding agent is connected to a detectable label. Detectable labels can include, for example, light absorbing dyes, fluorescent dyes, or radioactive labels. Detectable labels, methods for detecting them, and methods for incorporating them into reagents (e.g., antibodies and nucleic acid probes) are well known in the art.

[0093] In some embodiments, in some embodiments, the detectable label can include a label that can be detected by spectroscopy, photochemistry, biochemistry, immunochemistry, electromagnetic, radiochemistry or chemical means (e.g., fluorescence, chemiluminescence or chemiluminescence), or any other appropriate means. The detectable label can be a primary label (wherein the label contains a directly detectable group or produces a directly detectable group); or a secondary label (wherein the detectable label is combined with another group to produce a detectable signal, for example, the common use of secondary and tertiary antibodies in immunolabeling). The detectable label can be covalently or non-covalently attached to the reagent. Alternatively, the detectable label can be connected, for example, by direct labeling through a ligand-receptor binding pair arrangement or other such specific recognition molecules to achieve a molecule that is bound to the reagent. The detectable label can include, but is not limited to, radioisotopes, bioluminescent compounds, chromophores, antibodies, chemiluminescent compounds, fluorescent compounds, metal chelates and enzymes.

[0094] In some embodiments, the expression levels of multiple markers of the invention can be determined simultaneously (eg, multiplexed) or in parallel.

[0095] In other embodiments, the gene expression products (proteins) associated with the biomarkers of the present invention can be detected to determine the presence of EPC subpopulations. These detection techniques are known to those skilled in the art and include, for example, ELISA (enzyme-linked immunosorbent assay), western blot, FACS, radioimmunoassay; (RIA); sandwich assay; fluorescence in situ hybridization (FISH); immunohistological staining; immunoelectrophoresis; immunoprecipitation and immunofluorescence using detection reagents (e.g., antibodies or protein binders).

[0096] In some embodiments, the product is selected from a kit.

[0097] The kit can also include instructions for using the kit components to implement the method. The instructions for implementing the method are usually recorded on a suitable recording medium. For example, the instructions can be printed on a substrate, such as paper or plastic, etc. The instructions may be present in the kit in the form of a package insert or on a label of a container of the kit or its components (e.g., associated with a package or subpackage).

[0098] Another aspect of the present invention provides a method for determining the purity of a differentiation product, the method comprising:

[0099] The expression level of at least one biomarker of cells in the sample of the differentiation product is detected, wherein the biomarker is selected from CD144, vWF and / or CD133; and the purity of the differentiation product is determined according to the expression level of the biomarker.

[0100] In some embodiments, the cells in the sample are present in the form of a cell mixture, a cell aggregate, or a tissue.

[0101] Another aspect of the present invention provides a method for quantifying EPC subpopulations in a sample, the method comprising:

[0102] The expression level of at least one biomarker of cells in the target sample is detected, wherein the biomarker is selected from CD144, vWF and / or CD133; and the content of the EPC subpopulation is determined according to the expression level of the biomarker.

[0103] In some embodiments, at least one cell having the following expression profile is a late EPC: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - .

[0104] In some embodiments, at least one cell having the following expression profile is an early EPC: CD133 高 / + 、CD144 低 / - and / or vWF 低 / - .

[0105] In some embodiments, the sample of interest comprises a mixture of cells of EPCs.

[0106] In some embodiments, the target sample comprises a mixture of various types of cells. When the target sample comprises a mixture of various types of cells, the method for quantifying EPC subpopulations in the sample may further include detecting the expression level of markers that confirm EPCs in addition to detecting the expression level of the aforementioned biomarkers.

[0107] On the other hand, the present invention provides a method for screening candidate drugs that regulate EPC subpopulations, the method comprising adding a substance to be screened to a cell population, detecting the expression level of a biomarker of the cell, wherein the biomarker is selected from CD144, vWF and / or CD133; when the substance to be screened changes the expression level of the cell marker, the drug to be screened is a candidate drug for regulating EPC subpopulations.

[0108] In some embodiments, if the substance to be screened is added, the marker has the following increased expression profile CD144 高 / + 、vWF 高 / + 、CD 133 低 / - , then the substance to be screened is a candidate drug for promoting late EPC.

[0109] In some embodiments, if the substance to be screened is added, the marker has the following increased expression profile: CD133 高 / + 、CD144 低 / - and / or vWF 低 / - , then the substance to be screened is a candidate drug for promoting early EPC.

[0110] In one aspect, the present invention provides a method for treating ischemic diseases, comprising administering to a subject an effective amount of advanced EPC or the pharmaceutical composition described above in the present invention.

[0111] In some embodiments, advanced EPCs for treatment can be obtained by the methods described in the examples of the present application.

[0112] In some embodiments, late EPCs for treatment can be obtained by the aforementioned methods for isolating or enriching late EPCs.

[0113] A "therapeutically effective amount" will be the amount of an agent that can prevent or at least slow down (mitigate) a medical condition such as ischemic disease, especially lower limb ischemia. The dosage and administration of the disclosed cells or pharmaceutical compositions can be determined by a person of ordinary skill in the field of clinical pharmacology or pharmacokinetics. The effective amount of the active agent of the present invention used therapeutically will depend on, for example, the therapeutic goal, the route of administration, and the patient's condition. Accordingly, it may be necessary for the therapist to adjust the dosage and change the route of administration as needed to obtain the best therapeutic effect.

[0114] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0115] Example 1 Directed differentiation and identification of early EPC

[0116] Preparation of culture medium

[0117] Preparation of E8 complete medium: Prepare E8 complete medium according to Table 1 and store at 4°C for up to 2 weeks.

[0118] Table 1E8 Complete medium preparation table

[0119] Reagents Manufacturer Part Number Final concentration / volume E8 Basal Medium Stemcell 05991 450mL E8 25×Supplement Stemcell 05992 20mL Penicillin-Streptomycin Invitrogen 15140122 1%

[0120] Preparation of differentiation basal medium: Prepare differentiation basal medium according to Table 2 and store at 4°C for up to 1 month.

[0121] Table 2 Preparation of differentiation basal medium

[0122]

[0123] 1. iPSCs recovery and passaging

[0124] 1.1 Matrigel coating

[0125] (1) In an ice box, open the 1.5 mL EP tube containing matrigel with the help of hemostats.

[0126] (2) Pipette 100 μL of pre-cooled coating solution into the EP tube containing matrigel, pipette and vortex repeatedly, and then pipette the supernatant back into the centrifuge tube. This process needs to be repeated several times, and the matrigel should be dissolved as quickly as possible. Do not rewarm the tube. The dilution of matrigel is 1:400.

[0127] (3) Take out the pre-cooled objects to be coated and place them on an ice box. Mix the coating solution with an electric pipette and use a suitable measuring vessel to coat the following volumes: T75: 12 mL per bottle; T25: 4 mL per bottle; 6-well plate: 2 mL per well; 12-well plate: 1 mL per well; 24-well plate: 0.5 mL per well; 48-well plate: 0.25 mL per well.

[0128] (4) Place the coated culture flask / plate in a 37°C, 5% CO2 incubator and incubate overnight.

[0129] 1.2 iPSCs recovery

[0130] (1) Prepare E8 complete medium containing 10 μM Y-27632 according to the amount of medium required for recovery. Add 1 μL Y-27632 (10 mM) stock solution per mL of medium and preheat at room temperature.

[0131] (2) Prepare 10-15 mL of E8 medium and preheat it in a 37°C water bath.

[0132] (3) Take out a cryovial from the liquid nitrogen tank and immediately place it in a 37°C water bath. Shake it back and forth for 60-90 seconds to completely melt the frozen cell suspension.

[0133] (4) Once the cells in the cryotube are completely thawed (liquid), immediately remove them from the hot water bucket, thoroughly disinfect the surface of the cryotube with 75% alcohol, and place them in the clean bench. When the cryotube is about to thaw, place the centrifuge tube containing E8 culture medium preheated to 37°C in the clean bench after disinfection with alcohol.

[0134] (5) Under strict aseptic operation conditions, remove the cell suspension from the cryopreservation tube and inject it into a 15 mL centrifuge tube with preheated E8 medium. Gently pipette 2 to 3 times and centrifuge at 200 g for 5 min. After centrifugation, discard the supernatant.

[0135] (6) Add E8 medium containing 10 μM Y-27632, gently blow 2 to 3 times, and remove the Matrigel-coated plate / culture bottle from the incubator. Aspirate the coating solution and gently add the cell suspension along the uncoated surface (do not add directly onto the coating layer). Place the culture dish in the incubator for culture.

[0136] Note: When thawing, choose the inoculation container according to the number of cells. Generally, 500,000 to 800,000 cells are inoculated in a 6-well plate, 800,000 to 1,000,000 cells are inoculated in a T25 flask, and 1,000,000 to 2,000,000 cells are inoculated in a T75 flask.

[0137] 1.3 iPSCs digestion and passaging;

[0138] (1) Prepare TrypLE working solution: pipette 5 mL of DPBS into a new 15 mL centrifuge tube, then add 5 mL of TrypLE stock solution and mix well to obtain the working solution.

[0139] (2) Prepare E8 complete medium containing 10 μM Y-27632 according to the amount of culture medium required for subculturing. Add 1 μL of Y-27632 (10 mM) stock solution per mL of culture medium.

[0140] (3) Take out the well plate / culture bottle to be subcultured from the incubator, discard the supernatant, and wash twice with DPBS (the amount of DPBS used each time should not be less than the amount of the original culture medium), each time for 1 min (when washing, leave the DPBS in the well / bottle for 30-45 seconds before aspirating it).

[0141] (4) After adding TrypLE working solution (add about 1 mL of TrypLE working solution to the six-well plate and about 2 mL of TrypLE working solution to the T25 bottle), place the plate in an incubator and incubate for 2-5 min. During this time, the cells can be observed under a microscope and shrink, become round, and disperse.

[0142] (5) Gently tap the culture flask / plate to detach the cells from the bottom of the plate, then gently pipette up and down several times, and finally add DMEM / F12 to terminate digestion.

[0143] (6) After balancing, centrifuge at 200 g for 5 min. After centrifugation, discard the supernatant, gently shake the bottom of the centrifuge tube, add 5 mL of E8 complete medium containing 10 μM Y-27632 to resuspend the cells, inoculate the cell suspension into a T25 flask coated with matrigel, and place the culture flask in a 37°C, 5% CO2 incubator for static culture.

[0144] (7) After 24 h of culture, the medium was completely replaced with fresh E8 complete medium.

[0145] (8) Thereafter, the medium was completely replaced every day, and cells were subcultured when the cell confluence reached about 70% to 80%.

[0146] Note: The number of iPSCs cells seeded is about 8000 cells / cm 2 According to different iPSCs lines, the subculture density can be adjusted so that the iPSCs cell subculture interval is 5 to 7 days.

[0147] 2. iPSCs induce early EPC differentiation process:

[0148] 2.1hiPSCs monolayer adherent cell formation (Day-1);

[0149] (1) Prepare TrypLE working solution: pipette 5 mL of DPBS into a new 15 mL centrifuge tube, then add 5 mL of TrypLE stock solution and mix well to obtain the TrypLE working solution.

[0150] (2) According to the amount of culture medium required for subculturing, prepare E8 complete culture medium containing 1% PS and 10 μM Y-27632 (ROCKi), and add 1 μL Y-27632 (10 mM) stock solution per mL of culture medium.

[0151] (3) Take out the well plate / culture bottle to be subcultured from the incubator, discard the supernatant, and wash twice with DPBS (the amount of DPBS used each time should not be less than the amount of the original culture medium), each time for 1 min (when washing, leave the DPBS in the well / bottle for 30-45 seconds before aspirating it).

[0152] (4) After adding TrypLE working solution (add about 1 mL of TrypLE working solution to the six-well plate and about 2 mL of TrypLE working solution to the T25 bottle), place the plate in an incubator and incubate for 2-5 min. During this time, the cells can be observed under a microscope and shrink, become round, and disperse.

[0153] (5) Gently tap the culture flask / plate to detach the cells from the bottom of the plate, then gently blow and swirl several times with a pipette, and finally add DMEM / F12 to terminate digestion. Pipette an appropriate amount of cell suspension for counting.

[0154] (6) After balancing, centrifuge at 200g for 5 min. After centrifugation, discard the supernatant, gently shake the bottom of the centrifuge tube, and resuspend in E8 complete medium containing 10 μM Y-27632 according to different cell densities. After the cells are fully mixed, drop the cell suspension into the wells of the culture plate, and the inoculation cell density is 8000 cells / cm 2 , placed in a 37°C, 5% CO2 incubator for static culture.

[0155] (7) After culturing for 24 h, the cells were washed twice with DPBS and then induced to differentiate.

[0156] 2.2 Mesendoderm differentiation induction process (Day 0-1)

[0157] (1) Prepare an appropriate amount of mesendoderm induction medium and preheat it in a 37°C water bath.

[0158] (2) Aspirate the original culture medium and add an appropriate amount of DPBS to wash the cells.

[0159] (3) Add mesendoderm induction medium and then place in a 37°C, 5% CO2 incubator for 24 hours.

[0160] Table 3 Preparation of mesendoderm differentiation medium

[0161] Reagents Manufacturer Part Number Final concentration Differentiation-based culture —— —— 1× CHIR 99021 Selleck S2924 10μM

[0162] 2.3 Mesoderm differentiation induction process (Day 1-3)

[0163] (1) Prepare an appropriate amount of mesoderm-specific culture medium and preheat it in a 37°C water bath.

[0164] (2) Aspirate the original culture medium and add an appropriate amount of DPBS to wash the cells.

[0165] (3) Add mesoderm-specific culture medium and then place in a 37°C, 5% CO2 incubator for 48 h.

[0166] Table 4 Preparation of mesoderm differentiation medium

[0167] Reagents Manufacturer Part Number Final concentration Differentiation-based culture —— —— 1× VEGF165 Peprotech AF-100-20 20 ng / mL FGF Peprotech AF-100-18B 20 ng / mL

[0168] 2.4 Operational procedures for early EPC differentiation induction (Day 3-9)

[0169] (1) Prepare an appropriate amount of early EPC differentiation medium and preheat it in a 37°C water bath.

[0170] (2) After 48 hours of mesoderm specialization, the original culture medium was discarded; an appropriate amount of DPBS was added to wash the cells, and the cells were digested to single cells with TrypLE working solution to terminate cell digestion. After centrifugation at 200g for 5 minutes, the cells were resuspended in early EPC differentiation medium and cultured at 10,000 cells / cm 2 The cells were inoculated and then placed in a 37°C, 5% CO2 incubator for static culture.

[0171] (3) Thereafter, the medium for early EPC differentiation was replaced with fresh medium on days 4 and 5 of differentiation.

[0172] (4) On the 6th day of differentiation, the original culture medium was discarded; an appropriate amount of DPBS was added to wash the cells, and the cells were digested to single cells with TrypLE working solution to terminate the cell digestion. After centrifugation at 200g for 5 min, the cells were resuspended in early EPC maintenance medium and cultured at 1000 cells / cm 2 The cells were inoculated and then placed in a 37°C, 5% CO2 incubator for static culture.

[0173] (5) Thereafter, fresh early EPC maintenance medium was replaced on days 7 and 8 of differentiation.

[0174] (6) On the 9th day of differentiation, the original culture medium was discarded; an appropriate amount of DPBS was added to wash the cells, and the cells were digested into single cells with TrypLE working solution to terminate the cell digestion. After centrifugation at 200g for 5 min, the early EPC cells were harvested for freezing and quality inspection.

[0175] Table 5 Preparation of early EPC differentiation medium

[0176]

[0177]

[0178] Table 6 Preparation of early EPC maintenance medium

[0179] Reagents Manufacturer Part Number Final concentration Differentiation-based culture —— —— 1× VEGF165 Peprotech AF-100-20 20 ng / mL

[0180] Example 2 Directed differentiation and identification of late EPC

[0181] Preparation of basal culture medium

[0182] Preparation of mesoderm induction basal medium: Prepare it according to the specifications and proportions shown in Table 7 and store it at 4°C for up to 1 month. B-27minus insulin should be packaged in single doses and stored at -20°C. Avoid repeated freezing and thawing. Take out one tube of each medium one day before use and thaw it overnight at 4°C, or thaw it at room temperature on the same day.

[0183] Table 7 Preparation of mesoderm induction basal medium

[0184] Total volume 1000mL 500mL 100mL 50mL DMEM / F12 medium 500mL 250mL 50mL 25mL Neurobasal medium 500mL 250mL 50mL 25mL N-2(100X) 10 mL 5mL 1mL 0.5mL B-27minus insulin(50X) 20mL 10mL 2mL 1mL β-Mercaptoethanol 1mL 0.5mL 0.1mL 0.05mL

[0185] Preparation of EPCs induction basal medium: Prepare it immediately before use according to the specifications and proportions shown in Table 8, and store it at 4°C for up to 1 month. Among them, StemPro-34 Supplement needs to be divided into single-use amounts and stored at -20°C. Avoid repeated freezing and thawing. Take out one tube and thaw it at 4°C overnight one day before use, or thaw it at room temperature on the same day.

[0186] Table 8 Preparation of EPCs induction basal medium

[0187] Total volume 500mL 100mL 50mL StemPro-34SFM medium 500mL 100mL 50mL StemPro-34Supplement 13mL 2.6mL 1.3mL GlutaMAX(100X) 5 mL 1 mL 0.5mL

[0188] 1. Recovery and Passaging of iPSCs

[0189] (1) Take out a tube of frozen iPSC cells from the iPSCs working bank and quickly transfer it to the laboratory. Place it in a hot water bath at 38℃-40℃ and shake it gently. When only tiny (about the size of a millet grain) crystals remain in the cryopreservation tube, thoroughly disinfect the surface of the cryopreservation tube with 75% alcohol and place it in an ultra-clean workbench.

[0190] (2) Use a pipette to transfer the cell suspension to a 15 mL centrifuge tube, add 5 mL of DMEM / F12 Medium preheated at 37°C, and centrifuge at 200 g for 5 min at room temperature.

[0191] (3) After centrifugation, discard the supernatant with a pipette. Then, add 1 mL of 37°C preheated E8 complete medium containing ROCKi (1 μL of ROCKi storage solution per mL of medium) using a 1 mL pipette tip. Gently pipette to resuspend the cell pellet and aspirate 10 μL for cell counting and viability detection.

[0192] (4) Take out the prepared Matrigel-coated cell culture plate from the 37°C / 5% CO2 cell culture incubator, take a T25 culture flask as an example, remove the liquid, and add 5 mL of E8 complete medium containing ROCKi preheated at 37°C.

[0193] (5) Then slowly add an appropriate amount of cell dilution solution (seeding density 1.0-1.5×10 4 Cell clusters / cm 2 ), put the cell bottle into a 37℃ / 5% CO2 cell culture incubator, shake it back and forth and left and right for about 10 times (short, flat, and fast) to ensure that the cells are evenly distributed on the bottom of the culture bottle, and then let it stand overnight. The iPSCs inoculated after recovery are at the P13 generation.

[0194] (6) After 24 hours, replace with fresh E8 complete medium preheated at 37°C. Repeat the medium change every day until the cell aggregation degree increases to 70-80%, or the diameter of any single colony is larger than 10× the microscopic field of view. Then, iPS cells can be passaged according to steps (3)-(7).

[0195] (7) The inoculation density of each generation is fixed at 1.0-1.5×10 4 Cell clusters / cm 2 The fixed amplification time is 4 days, and the cells are subcultured every 4 days. After the P14 generation has been amplified for 4 days, the next step is entered.

[0196] 2. Operational procedures for establishing iPSCs monolayer differentiation (Day-1)

[0197] (1) After formally starting the induction of iPSCs differentiation, the cells were centrifuged normally, the supernatant was removed, and an appropriate amount of E8 complete medium containing ROCK preheated at 37°C was added. The cell pellet was resuspended by gently pipetting, and then the resuspended cell fluid was counted and the viability was tested.

[0198] (2) Take out four Matrigel-coated T75 culture flasks from the 37°C / 5% CO2 cell culture incubator, remove the liquid, and add 13 mL of 37°C preheated E8 complete medium containing ROCK to each flask.

[0199] (3) The initial seeding density of iPSCs induced differentiation should be controlled at 3.0×10 4 ~4.0×104 cells / cm 2 According to the density of the cell resuspension after counting, add an appropriate volume of the cell resuspension into the Matrigel-coated T75 culture flask prepared above.

[0200] (4) Place the cell plate in a 37°C / 5% CO2 cell culture incubator, shake it back and forth and left and right for about 10 times to ensure that the cells are evenly distributed on the culture plate, and then let it stand overnight.

[0201] (5) After 24 hours, observe the polymerization degree of iPSCs after inoculation. If the polymerization degree reaches 15-25%, you can directly proceed to the subsequent formal induction step. If the polymerization degree does not reach 15%, you can replace it with fresh E8 complete medium preheated at 37°C and appropriately extend the iPSCs culture time to 12-24 hours.

[0202] 3. Operational procedures for the induction of lateral plate mesoderm (Day 0-3)

[0203] (1) After the iPSC cells are seeded, when the degree of aggregation reaches about 15-25%, formal differentiation induction begins, which is defined as Day 0. Remove the old culture medium in the T75 flask, wash it with 10 mL DPBS, and then add 30 mL of 37°C preheated mesoderm induction complete medium-1 to each flask, followed by incubation in a 37°C / 5% CO2 cell culture incubator for 17-18 hours.

[0204] Table 9 Mesoderm Induction Complete Medium-1

[0205]

[0206] (2) After 17-18 hours of incubation (Day 1), iPS cells gradually spread out, the nuclear-cytoplasmic ratio decreased, and the cell area increased. Remove the old culture medium in the T75 flask, wash it with 10 mL DPBS, and then add 50 ml of 37°C preheated mesoderm induction complete medium-2 to each flask, and then incubate in a 37°C / 5% CO2 cell culture incubator for 2 days without changing the medium.

[0207] Table 10 Mesoderm induction complete medium-2

[0208]

[0209] 4. Operational procedures for induction of late EPCs (Day 3-6)

[0210] (1) After the formation of the lateral plate mesoderm cells on Day 3, remove the old culture medium in the T75 flask, wash it with 10 mL of DPBS, and then add 30 mL of EPCs induction complete medium (prepared according to the table below) preheated at 37°C to each flask. Return the culture plate to the 37°C / 5% CO2 cell culture incubator and incubate for 24 hours.

[0211] Table 11 Preparation of complete medium for EPCs induction

[0212]

[0213]

[0214] (2) One day later (Day 4), repeat the medium change operation of Day 3, and add 30 mL of 37°C preheated EPCs induction complete medium (prepared according to the above table) to each bottle. Incubate for 24 hours until Day 5, and EPCs with a higher EC tendency will be induced.

[0215] (3) At least 1 hour before enzymatic dissociation and replating of EPCs on Day 5, prepare 8 Fibronectin-coated T175 cell culture flasks.

[0216] (4) Remove all old culture medium from T75 flasks, wash twice with DPBS, then add 3 mL of TrypLE to each flask and place in a 37°C / 5% CO2 cell culture incubator for 3-5 min. Observe the degree of cell detachment under a microscope until most of the cells begin to float.

[0217] (5) Gently shake the bottom of the culture flask until most of the cells fall off in a quicksand-like state. Add 12 mL of DMEM / F12 Medium to neutralize the digestion effect of TrypLE. Use a pipette to gently blow the detached cells to resuspend them. Then transfer them to a centrifuge tube and take an appropriate amount of cells for counting.

[0218] (6) Centrifuge at 200 g for 5 min at room temperature. During this time, prepare EPCs maintenance complete medium (prepare according to the table below).

[0219] Table 12 Preparation of complete culture medium for EPCs maintenance

[0220]

[0221] (7) Remove the Fibronectin working solution from the T175 bottle that has been standing at room temperature for 1 hour, and rinse twice with an appropriate amount of double distilled water. Remove the supernatant of the centrifuged cells, take an appropriate amount of prepared EPCs maintenance complete medium to resuspend the cells, and then add the cells (one T75 bottle to two T175 bottles) evenly to the T175 bottles (35 ml / T175 bottle).

[0222] (8) Place the culture flask in a 37°C / 5% CO2 cell culture incubator and let it stand overnight.

[0223] (9) 24 h later (Day 6), the cells were allowed to adhere and washed once with an appropriate amount of DPBS. Each T175 flask was then digested with 6 mL of TrypLE and terminated with 24 mL of DMEM / F12. The cells were centrifuged at 200 g for 5 min and the supernatant was removed.

[0224] (10) Use a pipette to take up a small amount of DPBS and gently blow to resuspend each cell pellet. Then transfer the pellet to the same 50 mL centrifuge tube to ensure that the total volume is not less than 40 mL. Centrifuge at 200 g for 5 min and discard the supernatant.

[0225] (11) Resuspend and wash again with 40 mL of DPBS, and take 50 μL for counting and viability detection.

[0226] (12) Based on the cell density obtained from the test and the quantity required for quality control, take the corresponding volume of cell suspension and send it to the quality inspection department for various quality tests of the product.

[0227] (13) The remaining cell suspension was centrifuged again at 200 g for 5 min and cryopreserved as EPCs stock solution according to the subsequent operation procedures.

[0228] Example 3 Immunofluorescence detection of EPC molecular markers

[0229] Table 13 Reagents

[0230]

[0231] Table 14 Working fluid

[0232]

[0233]

[0234] Steps:

[0235] (1) Accurately count the cryopreserved EPC cells after passage or resuscitation, and calculate the total number of cells based on the counting results. Take about 1×10 EPC cells by volume ratio. 6 cells, divided into 8 wells, each well has about 100,000-150,000 cells. The final volume of EPC complete medium in each well is 0.5 mL. Mark the inoculation wells for the purpose of the experiment, the test person and the inoculation time. Place in a 37℃ 5% CO2 cell culture incubator and culture until the confluence reaches more than 60%.

[0236] (2) Aspirate and discard the liquid in the used wells and wash three times with 500 μL DPBS.

[0237] (3) Add 200 μL of fixative (4% paraformaldehyde) to each well and incubate at room temperature for 20 min.

[0238] (4) Aspirate the fixative and wash three times with 200 μL DPBS.

[0239] (5) Add 200 μL of 0.1% Triton-X 100 and incubate at room temperature for 15 min.

[0240] (6) Discard the supernatant and wash three times with 200 μL DPBS.

[0241] (7) Add 200 μL of 5% BSA blocking solution to each well and let stand at room temperature for 30 min.

[0242] (8) Aspirate the supernatant from the test wells and add 200 μL of primary antibody working solution (5% BSA 100-fold diluted primary antibody as primary antibody working solution) and incubate overnight at 4°C. Negative control wells were left untreated and incubated overnight at 4°C.

[0243] (9) Discard the supernatant and wash three times with 200 μL DPBS.

[0244] (10) Add 200 μL of secondary antibody working solution (dilute the secondary antibody 100-fold in DPBS to prepare the secondary antibody working solution) to each well and incubate at room temperature in the dark for 1 h.

[0245] (11) Discard the supernatant and wash three times with 200 μL DPBS.

[0246] (12) Add 200 μL of DAPI working solution (DAPI diluted 200-fold in DPBS) to each well and incubate at room temperature for 2 min in the dark. Wait for observation and photography under a microscope in a dark room.

[0247] Experimental results and conclusions:

[0248] Immunofluorescence test results Figure 1 and Figure 2 As shown, both early EPC and late EPC highly expressed CD31, CD34 and KDR; late EPC also highly expressed CD144 and vWF, but early EPC lowly expressed or even did not express CD144 and vWF.

[0249] Conclusion: CD144 and vWF can be used as marker genes to distinguish early EPC from late EPC. Example 4 Detection of EPC molecular markers by flow cytometry

[0250] Table 15 Reagents

[0251]

[0252] Steps:

[0253] (1) Accurately count the EPC cells of the cryopreserved test sample after passage or thawing, and calculate the total number of cells based on the counting results. Take about 5×10 6 cells, centrifuged at 350g for 5 min, and transferred to a 1.5mL EP tube with 1mL DPBS. The cells collected in this step should be prepared into a single-cell suspension using an appropriate method to prevent cell clumps from blocking the flow system or affecting data accuracy.

[0254] (2) The test samples were grouped, packaged and labeled in 1.5 mL EP tubes according to the experimental settings. Seven groups were set up, with 100 μL of cell suspension in each tube, labeled Blank (blank control group), 647 and 488 (negative control group), KDR, CD34, CD31 and CD133 respectively.

[0255] (3) Prepare a mixture of DPBS and antibody at a ratio of 100:5 μL and incubate at room temperature in the dark for 30 min. Centrifuge for 120 s in a microcentrifuge, discard the supernatant and break up the cell pellet.

[0256] (4) Washing: Add 500 μL of DPBS to each tube for washing, centrifuge for 120 seconds, discard the supernatant and break up the cell pellet. Repeat the washing operation twice, for a total of 3 times.

[0257] (5) Flow cytometry: Add 200 μL of DPBS to each tube of sample to be tested and resuspend it. Then load the sample onto the flow cytometer. After the test is completed, save the document and analyze the flow cytometry results using analysis software.

[0258] Experimental results and conclusions:

[0259] Test results such as Figure 3 and 4 As shown, both early EPC and late EPC highly expressed CD31, CD34 and KDR. Early EPC also expressed CD133, while late EPC expressed low or even no CD133. Conclusion: CD133 can be used as one of the surface markers of early EPC and late EPC.

[0260] Example 5 In vitro tube formation experiment to detect the angiogenesis ability of EPC

[0261] (1) The EPCs prepared in Example 1 and Example 2 were cultured in T25 culture flasks for 3 days, the culture supernatant in the T25 cell culture flasks was discarded, the cells were washed twice with 3 mL DPBS, 1 mL TrypLE enzymatic solution was added, and the cells were placed in a 37° C. 5% CO2 cell culture incubator for digestion for 3 to 5 min. The degree of cell detachment was observed under a microscope until most of the cells began to float.

[0262] (2) Gently shake the bottom of the culture flask until most of the cells fall off in a quicksand-like state. Then add 2 mL of culture supernatant to neutralize the digestion effect of TrypLE. Use a pipette to gently blow the detached cells to resuspend them. Then transfer all the cell resuspension to a 15 mL centrifuge tube and centrifuge at 300 g for 5 min at room temperature.

[0263] (3) After centrifugation, discard the supernatant, add 0.5 mL of EPC maintenance complete medium to resuspend all cell pellets, and transfer all cell resuspension to a 15 mL centrifuge tube.

[0264] (4) Take 50 μL of cell resuspension and calculate the total number of cells.

[0265] (5) Take an appropriate amount of cell resuspension and place it in a new 15 mL centrifuge tube. Add EPC tube complete medium to a total volume of 350 μL and a total cell volume of 3.50 × 10 5 cells.

[0266] (6) After slowly pipetting twice with a 200 μL pipette tip, 100 μL of cell suspension per well was inoculated into a Matrigel-coated 48-well cell culture plate incubated at 37°C / 5% CO2 for 30 min, 0.1 mL / well, i.e., 1.0 x 10 5 cells / well, and place the 48-well cell culture plate in a 37°C / 5% CO2 cell culture incubator for static culture.

[0267] (7) After 6 hours, turn on the OLYMPUS optical inverted microscope, camera system, and computer and put them in standby mode.

[0268] Place the 48-well cell culture plate to be tested on the stage of the inverted microscope, adjust the light source and field of view of the inverted microscope, observe the tube formation results of the test sample, take photos and record them, and archive the photos.

[0269] Experimental results and conclusions:

[0270] The experimental results show that both early EPC and late EPC have the ability to form tubes (A), but there is no significant difference in the number of branches (B) and the average number of nodes (C) of tubes formed between early EPC and late EPC. There is a certain difference in the average tube length between early EPC and late EPC.

[0271] Conclusion: The ability to form tubes needs to be comprehensively judged from different dimensions. The above results show that both early EPC and late EPC have the ability to form tubes, but they cannot be used as a criterion for distinguishing early EPC from late EPC.

[0272] Example 6 Identification of late EPCs by acetylated LDL uptake and Ulex oleraceus lectin binding assay

[0273] Table 16 Reagents

[0274]

[0275] method:

[0276] (1) Accurately count the cryopreserved EPC cells after passage or resuscitation, and calculate the total number of cells based on the counting results. Take about 1×10 EPC cells by volume ratio. 6 cells, divided into 8 wells, each well has about 100,000-150,000 cells. The final volume of EPC complete medium in each well is 0.5 mL. Mark the well position for the purpose of the experiment, the test subject and the time of inoculation. Place in a 37℃ 5% CO2 cell culture incubator and culture until the confluence reaches more than 60% and then prepare for staining.

[0277] (2) Add fluorescent dye to the above detection wells at a ratio of 1 μL Dil-Ac-LDL per 100 μL culture medium and incubate at 37°C for 4 h.

[0278] (3) Aspirate the liquid in the wells and wash three times with DPBS, soaking for 5 min each time.

[0279] (4) Add 200 μL of 4% polymethanol to each well and fix for 10 min.

[0280] (5) Aspirate the liquid in the wells and wash three times with DPBS.

[0281] (6) Add 200 μL of FITC-UEA-Ⅰ working solution to each well and incubate at room temperature for 1 h.

[0282] (7) Aspirate the liquid in the wells, wash three times with DPBS, and add 200 μL DPBS.

[0283] (8) Observe and photograph under a fluorescence microscope in a dark room.

[0284] Experimental results and conclusions:

[0285] The experimental results are as follows Figure 5 As shown, red fluorescence marks acetylated LDL and green fluorescence marks UEA-Ⅰ. Acetylated low-density lipoprotein (Ac-LDL) cannot bind to LDL receptors after being modified, and is then taken up by macrophages and endothelial cells containing scavenger receptors that specifically recognize modified LDL, producing foam cells. Ulex oleraceus agglutinin (UEA) is a protein extracted from urease. Lectins play an important role in cell recognition and adhesion reactions, mainly promoting cell-to-cell adhesion. Lectins have more than one site for binding to sugars, so they can participate in cell recognition and adhesion to connect different cells. As can be seen in the figure, acetylated low-density lipoprotein (Ac-LDL) is rarely or even cannot be taken up by early EPC; late EPC can efficiently take up acetylated low-density lipoprotein (Ac-LDL).

[0286] Conclusion: There are significant differences in the phagocytic ability of acetylated low-density lipoprotein (Ac-LDL) between early EPC and late EPC, and late EPC has stronger phagocytic ability, which can be used as a functional test to distinguish early EPC from late EPC cells.

[0287] Example 7 Study on the efficacy of EPCs in treating lower limb ischemia in mice

[0288] Eighteen male Balb / c nude mice were selected and divided into three groups: model control group, early EPC and late EPC treatment groups, with 6 animals in each group. The lower limb ischemia model was established by double ligation and cutting of the femoral artery. After modeling, the treatment group was given the test endothelial progenitor cells (1×10 7 cells / kg); the model control group only established the model without drug administration. 14 days after drug administration, the lower limbs were scored and laser speckle blood flow was detected. The lower limb ischemia and function were determined by the test results, and the therapeutic effect of the test product on the lower limb ischemia of the animals was evaluated.

[0289] The results are as follows Figure 6 and 7 As shown in the figure, after early EPCs treatment, the lower limb ischemia rate of animals in each treatment group showed a downward trend to varying degrees compared with the model control group, but there was no statistical difference, indicating that the therapeutic effect of early EPCs was not significant; after late EPCs treatment, the lower limb ischemia rate of animals in each treatment group showed a significant decrease compared with the model control group, with statistical differences, indicating that late EPCs has a therapeutic effect on lower limb ischemia.

[0290] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. Application of late EPC in the preparation of drugs for the treatment of ischemic diseases; Preferably, the late EPC has at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - ; Preferably, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + and CD 133 低 / - combination of; Preferably, the late EPC also has at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + ; Preferably, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + ; Preferably, the EPCs are derived from iPSCs; Preferably, the ischemic disease is selected from lower limb ischemia.

2. A pharmaceutical composition for treating ischemic diseases, characterized in that: The pharmaceutical composition includes advanced EPC; Preferably, the late EPC has at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - ; Preferably, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + and CD 133 低 / - combination of; Preferably, the late EPC also has at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + ; Preferably, the late EPC has the following expression profile: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + ; Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier; Preferably, the pharmaceutical composition is in the form of an infusion; Preferably, the ischemic disease is selected from lower limb ischemia.

3. A method for identifying EPC subpopulations, characterized in that: The method comprises determining the expression of at least one biomarker in a cell, the biomarker comprising CD144, vWF or CD133; and When the cell is determined to have at least one of the following expression profiles, the EPC is a late EPC: CD144 高 / + 、vWF 高 / + 、CD 133 低 / - ; When it is determined that the cell has at least one of the following expression profiles, the EPC cell is an early EPC: CD133 高 / + 、CD144 低 / - 、vWF 低 / - ; Preferably, the method further comprises the step of identifying the cell as an EPC; Preferably, determining the expression of at least one biomarker in a cell comprises contacting the cell with a binding agent for said biomarker.

4. A method for identifying EPC subpopulations, characterized in that The method comprises detecting the phagocytic ability of the cell; Preferably, the late EPC subpopulation has a stronger phagocytic ability than the early EPC subpopulation; Preferably, the method detects the phagocytic ability of cells by detecting the uptake ability of acetylated LDL.

5. A method for sorting, isolating or enriching late EPCs from a cell population, characterized in that: Select cells with at least one of the following expression profiles: CD144 高 / + 、vWF 高 / + and / or CD 133 低 / - ; Preferably, the method comprises cells selected from the group consisting of: CD144 高 / + 、vWF 高 / + and CD133 低 / - ; Preferably, the method further comprises selecting cells having at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and / or KDR 高 / + ; Preferably, the method comprises selecting cells having the following expression profile: CD144 高 / + 、vWF 高 / + and / or CD 133 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + ; Preferably, the method further comprises culturing the late EPCs.

6. A method for sorting, isolating or enriching early EPCs from a cell population, characterized in that: Select cells with at least one of the following expression profiles CD133 高 / + 、CD144 低 / - and / or vWF 低 / - ; Preferably, the method comprises selecting cells expressing the following profile: CD133 高 / + 、CD144 低 / - and vWF 低 / - ; Preferably, the method further comprises selecting cells having at least one of the following expression profiles: CD31 高 / + 、CD34 高 / + and KDR 高 / + ; Preferably, the method comprises selecting cells having the following expression profile: CD133 高 / + 、CD144 低 / - and / or vWF 低 / - 、CD31 高 / + 、CD34 高 / + and KDR 高 / + .

7. A product, characterized in that The product comprises a binding agent for the biomarker, wherein the biomarker comprises CD144, vWF and / or CD133; Preferably, the biomarkers include a combination of CD144, vWF and CD133; Preferably, the biomarkers further include CD31, CD34 and / or KDR; Preferably, the biomarkers include a combination of CD144, vWF, CD133, CD31, CD34 and KDR; Preferably, the binding agent is selected from nucleic acids, ligands, enzymes, substrates and / or antibodies; Preferably, the binding agent is attached to a detectable moiety or label; Preferably, the product is selected from a kit.

8. A method for determining the purity of a differentiation product, characterized in that The method comprises: Detecting the expression level of at least one biomarker of cells in a sample of the differentiation product, wherein the biomarker is selected from CD144, vWF and / or CD133; determining the purity of the differentiation product according to the expression level of the biomarker; Preferably, the cells in the sample are in the form of a cell mixture, a cell aggregate or a tissue.

9. A method for quantifying EPC subpopulations in a sample, characterized in that: The method comprises: The expression level of at least one biomarker of cells in the target sample is detected, wherein the biomarker is selected from CD144, vWF and / or CD133; and the content of the EPC subpopulation is determined according to the expression level of the biomarker.

10. A method for screening candidate drugs for regulating EPC subpopulations, characterized in that: The method comprises adding a substance to be screened to a cell population, and detecting the expression level of a biomarker of the cell, wherein the biomarker is selected from CD144, vWF and / or CD133; when the substance to be screened changes the expression level of the cell marker, the drug to be screened is a candidate drug for regulating an EPC subpopulation.

Citation Information

Patent Citations

  • Method for inhibiting late endothelial progenitor cell function

    CN103784469A

  • Efficient amplification culture system for human vascular endothelial progenitor cells

    CN105331575A

  • Application of induced pluripotent stem cell differentiation-derived EPC to preparation of cerebral apoplexy therapeutic agent

    CN113633663A

  • Method for in vitro proliferation of cell populations containing cells suitable for treatment of ischemic diseases

    CN114164174A

  • Engineering mesodermal precursor cell compositions for the treatment or prophylaxis of perfusion disorders

    US20200281986A1

Cited By

  • Marker for characterizing EPC subpopulation, EPC subpopulation, and use thereof

    WO2026052047A1